Increased TGF-β levels in BLM administration promotes Smad 2/3 phosphorylation (canonical TGF-β pathway) and enhances the expression of fibrogenic genes, such as Col1a1 and α-SMA in the BLM-induced SSc model. The gene discussed is COL1A1; the disease is Bloom syndrome.